Business Wire1mon
PharmaEssentia Reaffirms its Commitment to Robust and Reliable Access to Interferon Therapies Amid Global Supply Challenges
BURLINGTON, Mass.--(BUSINESS WIRE)--In light of the reported global shortage of Pegasys® (peginterferon alfa-2a), PharmaEssentia (TWSE: 6446), a global biopharmaceutical company, reaffirms its ...
EurekAlert!20d
Peripheral blood CD4+/CD8+ t cell ratio predicts HBsAg clearance in inactive HBsAg carriers treated with peginterferon alpha
This study aimed to investigate the dynamics of peripheral blood T lymphocyte subsets during peginterferon alpha (peg-IFN-α) therapy and their association with hepatitis B surface antigen (HBsAg ...